Delcath Systems to Participate in the Lytham Partners Spring 2022 Investor Conference

Rhea-AI Summary

Delcath Systems, focused on interventional oncology, will participate in the Lytham Partners Spring 2022 Investor Conference. Key events include a presentation on April 4, 2022, at 11:00am ET, and a panel discussion on April 5, 2022, at 2:00pm ET, addressing technologies in cancer treatment. The company is known for its proprietary percutaneous hepatic perfusion system aimed at treating liver cancers, notably under the names HEPZATO in the U.S. and CHEMOSAT in Europe.

NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference, via presentation and panel discussion:

• Presentation
  • April 4, 2022, at 11:00am ET
  • Webcast link: https://wsw.com/webcast/lytham4/dcth/2015593.
    
    
• Panel Discussion - Latest Technologies to Combat Cancer
  
  
  • April 5, 2022, at 2:00pm ET
  • Webcast link: https://wsw.com/webcast/lytham4/panel3/2266953
    

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register at www.lythampartners.com/spring2022invreg.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, for the treatment of metastatic ocular melanoma (mOM), also known as metastatic uveal melanoma (mUM) and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).

In Europe, the PHP system is now regulated as a Class lll medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara
(646)-755-7412
james@haydenir.com

FAQ

When is the Delcath Systems presentation at the Lytham Partners Spring 2022 Investor Conference?

Delcath Systems will present on April 4, 2022, at 11:00am ET.

What is the focus of the panel discussion featuring Delcath Systems at the conference?

The panel discussion will focus on the latest technologies to combat cancer on April 5, 2022, at 2:00pm ET.

How can I view the Delcath Systems presentation online?

The presentation can be viewed via this webcast link.

Where can I find the webcast link for the Delcath Systems panel discussion?

The webcast link for the panel discussion is available here.

What products does Delcath Systems focus on for liver cancer treatment?

Delcath Systems is known for its proprietary percutaneous hepatic perfusion system, marketed as HEPZATO in the U.S. and CHEMOSAT in Europe.